Molecular Partners to Participate in Upcoming Healthcare Investor Conferences
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm specializing in DARPin therapeutics, will participate in two investor events in May.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm specializing in DARPin therapeutics, will participate in two investor events in May. The company is set to publish its Q1 2022 earnings report on May 12, 2022, after NASDAQ trading hours. Key events include the RBC Capital Markets Global Healthcare Conference from May 17-18, featuring a fireside chat on May 17 at 9:00 am ET, and BioEquity Europe 2022 with virtual meetings on May 23-24. Presentations will be available online.
Details
News Market Reaction – MOLN
The recorded move for MOLN in the trading session of this news was -2.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its management team will participate in two upcoming investor events. In addition, the Company will publish its Q1 2022 earnings report on May 12, after the close of trading at the NASDAQ exchange.
Conference Details:
- 2022 RBC Capital Markets Global Healthcare Conference, in-person, May 17-18, 2022
- Fireside chat – Tuesday, May 17, 2022, at 9:00am ET
- Fireside chat – Tuesday, May 17, 2022, at 9:00am ET
- BioEquity Europe 2022 – virtual 1x1 meetings, Monday-Tuesday, May 23-24, 2022
- Virtual presentation made available on-demand
Presentations will be made available through the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.